Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19
NCT04904549Phase 3Terminated
- Sponsor
- Sanofi
- Start
- May 2021
- Primary completion
- Aug 2024
- Modality
- Recombinant Protein Vaccines
- Countries
- 11
01
Overview
A Phase 3 trial of monovalent [B.1.351] CoV2 preS dTM-AS03 in coronavirus disease 2019 (COVID-19), sponsored by Sanofi. Started May 2021; status: terminated.
02
Drugs
monovalent [B.1.351] CoV2 preS dTM-AS03
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04904549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04904549.